A 7-day infusion of PGE1, an immunomodulator, was evaluated in a prospective, placebo-controlled, double-blinded trial in surgical patients with ARDS. The drug seemed to improve pulmonary function - only two PGE1 patients died with severe pulmonary failure compared with nine placebo patients (p=0.01). Survival at 30 days after the end of the infusion - the predetermined end point of the study - was significantly better in the pati ents given PGE1 (p=0.03), with 15 of 21 PGE1 patients (71%) alive at this time compared with seven of 20 placebo patients (35%). Improvement in overall survival in the PGE1 patients did not reach statistical significance (p=0.08). Overall survival in patients initially free of severe organ failure, however, was significantly better in the PGE1 patients (p=0.03). Of the six PGE1 patients free of severe organ failure at time of entry, all survived to leave the hospital; of the 10 placebo patients initially free of severe organ failure, four survived. The drug had no serious side effects and did not potentiate susceptibility to infection. PGE1 is a promising agent for the treatment of ARDS.
|Original language||English (US)|
|Number of pages||8|
|Journal||Seminars in Respiratory Medicine|
|State||Published - 1986|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine